The company plans to file a trial application with the FDA.
Bio-Light Israeli Life Sciences Investments Ltd. (TASE:BOLT) portfolio company IOptima Ltd. will begin a clinical trial of its second-generation non-invasive laser treatment for glaucoma, the OT-134, at a medical center in Mexico during the fourth quarter of 2007 and the first quarter of 2008. The trial will later be expanded to other locations worldwide.
Preclinical trials of the OT-134 were completed successfully in July.
IOptima plans to file a trial application with the US Food and Drug Administration (FDA).
Glaucoma is second most common cause of vision loss worldwide, affecting 2% of the world’s over-50 population. The US market for glaucoma treatment totals $2 billion a year, including both drugs and surgical procedures.
Published by Globes [online], Israel business news - www.globes.co.il - on November 4, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007